COMPASS Pathways (CMPS) Stock Analysis

What COMPASS Pathways does

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Key metrics

ETFs linked to CMPS

Broad-market and Healthcare sector ETFs an investor holding COMPASS Pathways is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CMPS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for COMPASS Pathways?

COMPASS Pathways trades under the ticker CMPS on NASDAQ.

Which exchange is CMPS listed on?

CMPS is listed on NASDAQ.

What sector does COMPASS Pathways operate in?

COMPASS Pathways is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CMPS in a portfolio?

PortView shows CMPS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.